InvestorsHub Logo
Followers 829
Posts 119624
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Wednesday, 06/07/2017 9:41:35 AM

Wednesday, June 07, 2017 9:41:35 AM

Post# of 751
ABBV’s Upadacitinib—(f/k/a ABT-494)—JAK inhibitor succeeds in RA phase-3:

https://finance.yahoo.com/news/abbvies-upadacitinib-abt-494-meets-115600772.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News